About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Jubilant Pharmova Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
530019
ISIN Demat
INE700A01033
Book Value
144.98
NSE Code
JUBLPHARMA
Dividend Yield %
0.47
Market Cap
169092.86
P/E
504.75
EPS
2.10
Face Value
1
BSE
NSE
05-Sep-2025 12:53
BSE
NSE
NSE F & O
05-Sep-2025 12:44
BSE
NSE
NSE F & O
Last Price
1061.60
Net Change
-3.1
% Change
-0.29%
Prev.Close
1064.70
Open
1065.00
High
1069.55
Low
1053.30
Volume
2460
Last Price
1062.20
Net Change
-2.6
% Change
-0.24%
Prev.Close
1064.80
Open
1064.80
High
1070.00
Low
1051.70
Volume
27503
Value
2611536
Best Buy
1061.20
Best Sell
1062.80
Best Quantity
29
Sell Quantity
4
Today's Range
1069.55
52-Week High
1309.00
52-Week Low
823.70
Value
29213686.6
Best Buy
1061.50
Best Sell
1062.20
Best Quantity
36
Sell Quantity
39
Today's Range
1070.00
52-Week High
1309.90
52-Week Low
802.00
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
29
Price
1061.20
Quantity
4
Price
1062.80
Best Bid
Best Offer
Quantity
36
Price
1061.50
Quantity
39
Price
1062.20
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Bonus
3 : 5
12-Mar-04
Book Closure
14-Sep-19
25-Sep-19
Dividend
500 %
25-Jul-25
Company News
02-09-2025
Jubilant Pharmova complet...
02-09-2025
Jubilant Pharmova gains o...
02-08-2025
Jubilant Pharmova informs...
02-08-2025
USFDA concludes PAI at J...
30-07-2025
Jubilant Pharmova informs...
13-06-2025
Jubilant Pharmova gets no...
20-03-2025
Jubilant Pharmova’s arm i...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.
